The Foundation Fighting Blindness VISIONS 2018 conference, June 21 – 23, 2018 at the Sheraton San Diego Hotel and Marina, will bring together the world’s leading vision scientists, assistive technologies experts, and the visually impaired community.
Get the inside scoop on this year’s top research advances and what’s next in retinal disease science by watching VISIONS 2018 LIVE!
We will be streaming several of our annual VISIONS conference sessions live on Friday, June 22 and Saturday, June 23. The sessions will be live streamed here on our blog, and our national Facebook as well.
Here’s the full schedule of live sessions:
Friday, June 22, 2018
The primary goal of the landmark study, funded by the Foundation, is to provide companies and researchers with disease-progression data and potential clinical trial endpoints to drive therapy development
Columbia, MD – More than 60 leading retinal disease clinical researchers from around the world gathered in Baltimore on June 11, 2018 to discuss findings from ProgStar, the Stargardt disease natural history study launched by the Foundation Fighting Blindness Clinical Research Institute (FFB-CRI) in 2013.
CheckedUp multimedia system will provide targeted disease and research information to retinal-disease patients in waiting and exam rooms at 1,000 ophthalmology practices in US.
The Foundation Fighting Blindness (FFB) will host its annual Love of Sight dinner on Tuesday, June 5, 2018 at The Ritz-Carlton, in Washington, D.C.
Horama, a French biotech developing gene therapies for rare eye diseases, was established in 2014 as a spin-off of INSERM, France’s public scientific and technology institute. Today, the company has three gene-therapy development programs underway for rare inherited retinal diseases, targeting people with mutations in the genes PDE6B, RPE65, and RLBP1.
Ben Shaberman will discuss how data enhances the research value of FFB’s patient registry for people with inherited retinal diseases
Results from ProgStar, FFB’s natural history study for people with Stargardt disease, to be used in Vitrisa’s simulation of clinical trial designs for potential therapies
Dr. Henry Klassen, jCyte co-founder and investigator at UC Irvine, provides an update in the video below on the clinical trials for an RP therapy derived from stem cells.
Dr. Christopher Brittain, Genentech medical director, discusses his company’s port delivery system, a tiny capsule implanted into the eye, for delivery of Lucentis® over a period of a few months. The device is currently in a Phase 2 clinical trial.